Tarsus Pharmaceuticals, Inc.
TARS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TARS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TARS
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for ophthalmic and other conditions, with its approved product XDEMVY and pipeline candidates including TP-04 for ocular rosacea and TP-05 for Lyme disease prophylaxis.
Key risk: Capital needs and financing risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$3.15B
Cash Runway
—
Lead Asset
TP-03 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 62 clinical trials for Tarsus Pharmaceuticals, Inc..
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for ophthalmic and other conditions, with its approved product XDEMVY and pipeline candidates including TP-04 for ocular rosacea and TP-05 for Lyme disease prophylaxis.
- As of June 30, 2026, Tarsus reported cash and equivalents of $206.6 million, total revenue of $173.9 million, and a net loss of $18.6 million for the six-month period [sec].
- The company's lead product, XDEMVY, is approved and commercialized, generating revenue to support ongoing operations [sec_mda · as of 2026-08-06].
- Pipeline programs include TP-04 for ocular rosacea and TP-05 for Lyme disease prophylaxis, both in clinical development [sec_mda · as of 2026-08-06].
- Tarsus has financed operations through equity offerings, debt, and product sales, and may require additional capital to fund future development and commercialization [sec_mda · as of 2026-08-06].
- The company faces risks related to reliance on third-party manufacturers, collaborators, and the need to maintain regulatory approvals [sec_mda · as of 2026-08-06].
What works
- XDEMVY is already approved and generating revenue, providing a commercial foundation and real-world validation of the company's development capabilities [sec_mda · as of 2026-08-06].
- The pipeline includes TP-04 and TP-05, targeting large markets (ocular rosacea and Lyme disease prophylaxis) with potential for significant growth [sec_mda · as of 2026-08-06].
- The company has a history of raising capital through multiple public offerings and a credit facility, indicating access to financial markets [sec_mda · as of 2026-02-23].
What to weigh
- Tarsus has a history of net losses and expects operating expenses to increase significantly as it commercializes XDEMVY and advances pipeline programs [sec_mda · as of 2026-08-06].
- The company may need additional capital to fully develop its product candidates, and adequate funding may not be available on acceptable terms [sec_mda · as of 2026-08-06].
- Tarsus relies on third parties for clinical trials and manufacturing, which introduces execution risk and potential delays [sec_mda · as of 2026-08-06].
- The company's ability to achieve or sustain profitability is uncertain, even if product sales grow [sec_mda · as of 2026-02-23].
From the filings
Quoted directly from source documents.
Tarsus expects operating expenses to increase as it commercializes XDEMVY and advances pipeline programs.
“We anticipate that our operating expenses will increase significantly as we: • continue to commercialize XDEMVY and our other product candidates for which we obtain regulatory approvals; • maintain regulatory approval for XDEMVY and seek regulatory approval for our other product candidates that successfully complete clinical development, if any; • advance the clinical development of various pipeline programs, including TP-04 for the potential treatment of ocular rosacea and TP-05 for the potential Lyme disease prophylaxis”
SEC MD&A · August 6, 2026
Tarsus may need additional capital and faces risks if funding is not available.
“Adequate funding may not be available to us when needed on acceptable terms, or at all.”
SEC MD&A · August 6, 2026
Tarsus relies on third parties for clinical trials and manufacturing.
“our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials”
SEC MD&A · August 6, 2026
The company has financed operations through equity, debt, and product sales.
“To date, we have financed our operations through private placements of preferred stock, convertible promissory notes, net proceeds from issuance of common stock in our IPO, our subsequent Follow-On Public Offerings and our 2023 ATM Prospectus, as well as proceeds from net product sales, our China Out-License, and drawdowns from the 2024 Credit Facility”
SEC MD&A · May 6, 2026
Risks & what to watch (4)›
Key risks
- Capital needs and financing risk — Tarsus may require additional capital to fund development and commercialization; adequate funding may not be available on acceptable terms [sec_mda · as of 2026-08-06].
- Reliance on third parties — The company depends on third parties for clinical trials and manufacturing, which could cause delays or failures [sec_mda · as of 2026-08-06].
- Profitability uncertainty — Tarsus has a history of net losses and may not achieve or sustain profitability even with growing product sales [sec_mda · as of 2026-02-23].
- Regulatory and IP risks — Maintaining regulatory approvals and protecting intellectual property are critical; failure could harm the business [sec_mda · as of 2026-08-06].
What to watch
- Progress of TP-04 clinical development for ocular rosacea and TP-05 for Lyme disease prophylaxis [sec_mda · as of 2026-08-06].
- Revenue growth trajectory of XDEMVY and its impact on the path to profitability [sec_mda · as of 2026-08-06].
- Any future capital raises or strategic collaborations to fund pipeline and operations [sec_mda · as of 2026-08-06].
- Regulatory decisions regarding XDEMVY label expansions or new approvals for pipeline candidates [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 23, 2026 · How we verify sources →
Run Tarsus Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tarsus Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.76 · 0% dilution
Lead: Approved
6 candidates
No upcoming catalysts tracked
0 buys · 32 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
252
Total value held
$3.13B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 4,481,926 | $314.4M |
| deep track capital, lp | 3,600,000 | $252.5M |
| blackrock, inc. | 3,552,612 | $249.2M |
| vanguard capital management llc | 3,521,082 | $247.0M |
| rtw investments, lp | 3,346,025 | $234.7M |
| morgan stanley | 1,944,272 | $136.4M |
| jennison associates llc | 1,712,124 | $120.1M |
| bank of america corp /de/ | 1,194,377 | $83.8M |
| tang capital management llc | 1,188,624 | $83.4M |
| geode capital management, llc | 1,121,091 | $78.7M |
Showing top 10 of 252 institutional holders of Tarsus Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 11.1%
- Days to cover
- 9.0
- Shares short
- 4,575,347
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TARS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tarsus Pharmaceuticals, Inc.?
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for ophthalmic and other conditions, with its approved product XDEMVY and pipeline candidates including TP-04 for ocular rosacea and TP-05 for Lyme disease prophylaxis.
What is Tarsus Pharmaceuticals, Inc.'s lead drug candidate?
Tarsus Pharmaceuticals, Inc.'s most advanced tracked candidate is TP-03 (Phase 2) for Meibomian Gland Dysfunction.
Who is the CEO of Tarsus Pharmaceuticals, Inc.?
Dr. Bobak R. Azamian M.D. is the chief executive officer of Tarsus Pharmaceuticals, Inc. (TARS).
Where is Tarsus Pharmaceuticals, Inc. headquartered?
Tarsus Pharmaceuticals, Inc. (TARS) is headquartered in Irvine, CA, United States.
What therapeutic areas does Tarsus Pharmaceuticals, Inc. focus on?
Tarsus Pharmaceuticals, Inc. develops therapies across Oncology, Neurology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Nephrology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.